Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The human aldo-keto reductase (AKR) 1C3, also known as type-5 17β-hydroxysteroid dehydrogenase and prostaglandin F synthase, has been suggested as a therapeutic target in the treatment of prostate and breast cancers. In this study, AKR1C3 inhibition was examined by Brazilian propolis-derived cinnamic acid derivatives that show potential antitumor activity, and it was found that baccharin (1) is a potent competitive inhibitor (K(i) 56 nM) with high selectivity, showing no significant inhibition toward other AKR1C isoforms (AKR1C1, AKR1C2, and AKR1C4). Molecular docking and site-directed mutagenesis studies suggested that the nonconserved residues Ser118, Met120, and Phe311 in AKR1C3 are important for determining the inhibitory potency and selectivity of 1. The AKR1C3-mediated metabolism of 17-ketosteroid and farnesal in cancer cells was inhibited by 1, which was effective from 0.2 μM with an IC(50) value of about 30 μM. Additionally, 1 suppressed the proliferation of PC3 prostatic cancer cells stimulated by AKR1C3 overexpression. This study is the first demonstration that 1 is a highly selective inhibitor of AKR1C3.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/np201002x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proviral functions of HMGB1 in HAdV-C5 replication compartments.
Microbiol Spectr
September 2025
Department of Viral Transformation, Leibniz Institute of Virology (LIV), Martinistraße, Hamburg, Germany.
Unlabelled: Human adenoviruses (HAdVs) induce significant reorganization of the nuclear environment, leading to the formation of virus-induced subnuclear structures known as replication compartments (RCs). Within these RCs, viral genome replication, gene expression, and modulation of cellular antiviral responses are tightly coordinated, making them valuable models for studying virus-host interactions. In a recent study, we analyzed the protein composition of HAdV type 5 (HAdV-C5) RCs isolated from infected primary cells at different time points during infection using quantitative proteomics.
View Article and Find Full Text PDFPurpose: To describe our integrated pelvic fascial structure-sparing (IPFSS) technique for robotic-assisted radical cystectomy (RARC) with intracorporeal orthotopic neobladder (ONB) reconstruction and to evaluate its impact on urinary continence and sexual function in male patients.
Methods: This retrospective observational study was conducted at a single high-volume center. Male bladder cancer patients who underwent IPFSS RARC with ONB were included.
A Precision Gene Engineered B Cell Medicine Producing Sustained Levels of Active Factor IX for Hemophilia B Therapy.
Mol Ther
September 2025
Be Biopharma, Cambridge, MA, 02139, USA. Electronic address:
Hemophilia B gene therapy treatments currently have not addressed the need for predictable, durable, active, and redosable factor IX (FIX). Unlike conventional gene therapy, engineered B Cell Medicines (BCMs) are durable, redosable, and titratable, and thus have the potential to address significant unmet needs in the Hemophilia B treatment paradigm. BE-101 is an autologous BCM comprised of expanded and differentiated B lymphocyte lineage cells genetically engineered ex vivo to secrete FIX-Padua.
View Article and Find Full Text PDFPde5a deficiency prevents diet-induced obesity via adipose cAMP-PKA activation enhancing fat browning.
Mol Metab
September 2025
Department of Experimental Medicine, Sapienza University of Rome, Rome, 00161, Italy. Electronic address:
Cyclic nucleotides are critical regulators of adaptive thermogenesis and adipogenesis, with their intracellular levels finely tuned by phosphodiesterases. Phosphodiesterase type 5 (PDE5A) modulates cyclic guanosine monophosphate (cGMP) levels in adipocytes. While PDE5A inhibition has shown promise in patients with diabetes, its role in metabolism remains unclear.
View Article and Find Full Text PDFAmniotic fluid stem cell therapy improves erectile function in a diabetic rat model.
Andrology
September 2025
Department of Urology, Knuppe Molecular Urology Laboratory, School of Medicine, University of California, San Francisco, California, USA.
Background: Current treatments for diabetic erectile dysfunction, such as phosphodiesterase type 5 inhibitors, penile injection, or vacuum erection devices, primarily offer symptomatic relief and do not address the underlying pathophysiology, which involves neural, vascular, and smooth muscle degeneration.
Objectives: This study aimed to evaluate the therapeutic potential of amniotic fluid-derived stem cells in a rat model of diabetic erectile dysfunction by assessing their impact on erectile function and penile tissue regeneration.
Methods: Male Sprague‒Dawley rats were divided into control, diabetic, and amniotic fluid-derived stem cell-treated diabetic groups.